EFNB2 and neoplasm: In summary, our studies provide comprehensive evidence to support the use of BIDEN-AP for targeting bi-directional EphB4/EFNB2 signaling to reduce tumor growth and metastasis and to overcome resistance to antiangiogenic therapy.